Philadelphia-Positive ALL Clinical Trial
Official title:
A Multicenter, Prospective Clinical Study of Olverembatinib Combined With Chemotherapy in the Treatment of de Novo Adult Philadelphia Chromosome-positive Acute Lymphoid Leukemia
In this study, adults with newly-diagnosed Philadelphia Chromosome-positive acute lymphoblastic leukemia (Ph+ ALL) will receive first-line therapy of a novel third-generation TKI Olverembatinib. The main purpose of the study is to evaluate the efficacy and safety of Olverembatinib in Ph+ ALL patients.
Eligible participants will receive an 28-day induction regimen of Olverembatinib (40mg, QOD) combined with VP-chemotherapy, followed by 4 cycles of Hyper-CVAD A/B treatment (each lasting 28 days). If complete molecular response (CMR) is achieved at the 3rd month, participants will receive another three cycles of Hyper-CVAD A/B treatment. Maintenance therapy would be given for at least 1 year with monthly courses of vincristine, prednisone and Olverembatinib. If participants fail to achieve CMR at the 3rd month, or patients with an available matched donor had the option to proceed to allogeneic stem cell transplantation (allo-HSCT) at the discretion of the treating physician. Olverembatinib would be administered at the time of hematopoietic reconstruction for at least 1 year. Intrathecal injection would be performed on day 15 of induction therapy and before each course of consolidation therapy to prevent central nervous system leukemia (CNSL). It is expected that about 55 patients will take part in this study. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04722848 -
Sequential Treatment With Ponatinib and Blinatumomab vs Chemotherapy and Imatinib in Newly Diagnosed Adult Ph+ ALL
|
Phase 3 | |
Recruiting |
NCT04475731 -
Ponatinib in Adult Ph+ ALL Patients With MRD Positivity or Hematological Relapse
|
Phase 2 | |
Not yet recruiting |
NCT05931757 -
A Study of Olverembatinib Combined With Blinatumomab in the Treatment of Ph+ ALL
|
Phase 2 | |
Recruiting |
NCT06287528 -
A Study of 19-28z/IL-18 in People With Acute Lymphoblastic Leukemia (ALL)
|
Phase 1 | |
Recruiting |
NCT06220487 -
A Single-arm, Open-label Study of Olverembatinib, CD3/CD19 Bispecific T-cell Engager, and Chidamide in Patients With Newly Diagnosed Ph+ALL
|
Phase 2 | |
Not yet recruiting |
NCT06175702 -
Treatment Protocol for Newky Diagnosed Adult Ph Positive ALL
|